- All Journals
- Al-Qadisiyah University
- Basrah University
- Kirkuk University
- Mosul University
- The Iraqi Borad for Medical Specialization
- University of Anbar
- University of Technology
- Al Mustafa University
- Al-Zahraa University for Women
- Alnoor University
- Kunooz University
- Misan University
- Ninevah University
- Tikrit University
- University of Al-Hamdaniya
- University of Kerbala
Effect of Oxidative Stress and dyslipidemia in hypertensive Iraqi patients | ||
| Journal of University of Anbar for Pure Science | ||
| Volume 19, Issue 1 - Serial Number 19, May and June 2025, Pages 32-38 PDF (886.89 K) | ||
| Document Type: Research Paper | ||
| DOI: 10.37652/juaps.2024.150394.1267 | ||
| Authors | ||
| Amna Adil Mohammed* 1; Maryam Ibrahim Salman1; Mohammed Ismael Dawood2 | ||
| 1Department of Biology, College of Sciences, University of Anbar, Ramadi, Iraq | ||
| 2Head of Department of Medicine, College of Medicine, University of AL Fallujah, Iraq | ||
| Abstract | ||
| Hypertension is a dangerous health issue, mostly due to its asymptomatic nature. The present study was designed to assess the malondialdehyde (MDA) as an indicator for oxidative stress and lipid profile in patients with hypertension in Anbar, Iraq. The study included 90 participants (50 hypertensive patients and 40 healthy people as controls), males and females aged 30–50 years. The patients were attending to an internal medicine consultation at Al-Ramadi Teaching Hospital. After drawing blood samples and serum separation the MDA level was measured using sandwich enzyme-linked immune-sorbent assay, lipid variables was measured using by the Chemistry Analyzer smart-150. The results showed a significant increase (P≤0.001) of systolic blood pressure (SBP) and diastolic blood pressure (DBP) in hypertension patients compared with the control group. The level of MDA showed a significant increase (P≤0.001) in patients compared with the control group. Also, the result indicated a significant increase (P≤0.022) in TG and VLDL in patients compared with the control and a significant increase (P≤0.003) in cholesterol and LDL, while there was a significant decrease in HDL in patients compared with the control (p≤0.003). The results showed a high level of oxidative stress in addition to a clear disorder in lipid profile in hypertensive patients, this indicates the potential role of both oxidative stress and dyslipidemia in the development of hypertension. | ||
| Keywords | ||
| Hypertension; lipid profile; Oxidative stress; Malondialdehyde | ||
| References | ||
|
[1] Wu H, Yu Z, Huang Q (2022). Characteristics of serum lipid levels in patients with hypertension: a hospital-based retrospective descriptive study. BMJ Open. 3;12(6):e054682. doi: 10.1136/bmjopen-2021-054682. PMID: 36547874; PMCID: PMC9171285.
[2] Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, Alexander L, Estep K, Hassen Abate K, Akinyemiju TF, Ali R, Alvis-Guzman N, Azzopardi P, Banerjee A, Bärnighausen T, Basu A, Bekele T, Bennett DA, Biadgilign S, Catalá-López F, Feigin VL, Fernandes JC, Fischer F, Gebru AA, Gona P, Gupta R, Hankey GJ etal. (2017). Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA. 2017 Jan 10;317(2):165-182. doi: 10.1001/jama.2016.19043. Erratum in: JAMA. 2017 Feb 14;317(6):648. PMID: 28097354.
[3] Yehya Abdul Hasan, M., Alfarttoosi, A., Abdul Hasan, M., Tawfeeq, W. F., & Alfarttoosi, A. J. (2021). Screening for Hypertension among Adults Attending Primary Health Care Centers. Iraqi Med J, 67(1), 20–25. https://www.researchgate.net/publication/357839177.
[4] Huang, Y., Chen, H., Liu, Q., Hu, J., Hu, D., Huang, Z., Xu, Z., & Wan, R. (2023). Obesity difference on association blood malondialdehyde level and diastolic hypertension in the elderly population: a cross-sectional analysis. European Journal of Medical Research, 28(1), 1–8. https://doi.org/10.1186/s40001-022-00983-7.
[5] Ana M, Briones, Rhian M, Touyz.Oxidative Stress and Hypertension: Current Concepts Current Hypertension Reports. 2010;12(2):135-142.
[6] Alam, R., Ahsan, H., & Khan, S. (2023). The Role of Malondialdehyde (MDA) and Ferric Reducing Antioxidant Power (FRAP) in Patients with Hypertension. Molecular and Cellular Biomedical Sciences, 7(2), 58. https://doi.org/10.21705/mcbs.v7i2.288
[7] Karadimas, T., & Meier, H. C. S. (2024). Association Between Coexisting Hypertension, Dyslipidemia, and Elevated C-Reactive Protein with Cardiovascular Disease in the Health and Retirement Study. University of Michigan Undergraduate Research Journal, 17(0), 159–174. https://doi.org/10.3998/umurj.5512.
[8] Diaba-Nuhoho, P., & Amponsah-Offeh, M. (2023). Metabolic Dysregulation in Cardiovascular Diseases: A Beat on Cardiometabolic Diseases. Current Trends in the Diagnosis and Management of Metabolic Disorders, October, 219–234. https://doi.org/10.1201/9781003384823-13.
[9] Whelton PK, Carey RM, Aronow WS. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American heart association Task force on clinical practice guidelines. J Am Coll Cardiol 20172018;71:e127–248.
[10] Khawaja TM, Shah SHA, Subhan Z, Mehmood I, M.& Shah M (2023). Effect of Losartan on Oxidative Stress and Lipid Profile in Patients with Essential Hypertension. Int.j.pathol.2023;21(1): 27 – 32.
[11] Daniel,W.W.; and C.L. Cross. (2018). Biostatistics: a foundation for analysis in the health sciences.
[10]Edition. John Wiley & Sons, Inc.. Library of Congress Cataloging-in-Publication Data. ISBN 978-1-118-30279-8.
[12] Forouzanfar MH, Liu P, Roth GA, et al.. Global burden of hypertension and systolic blood pressure of at least 110 to 115 MM Hg, 1990-2015. JAMA 2017;317:165–82. 10.1001/jama.2016.19043
[13] Cheng, W., Zhuang, J., & Chen, S. (2022). Dyslipidemia and the Prevalence of Hypertension: A Cross-Sectional Study Based on Chinese Adults Without Type 2 Diabetes Mellitus. Frontiers in Cardiovascular Medicine, 9(July), 1–12. https://doi.org/10.3389/fcvm.2022.938363.
[14] Olin, B. R., & Pharm, D. (2018). Hypertension : The Silent Killer : Updated JNC-8 Guideline Recommendations.
[15] Saseen J.J., & MacLaughlin E.J. (2017). Hypertension. DiPiro J.T., & Talbert R.L., & Yee G.C., & Matzke G.R., & Wells B.G., & Posey L(Eds.), Pharmacotherapy: A Pathophysiologic Approach, 10e. McGraw-Hill Education. https://accesspharmacy.mhmedical.com/content.aspx?bookid=1861§ionid=146233698.
[16] Hassan, A. A., & Sayyah, S. G. (2023). Oxidative Stress Marker Malondialdehyde and Glutathione Antioxidant in Hypertensive Patients. 2(1), 31–36.
[17] Verma, M. K., Jaiswal, A., Sharma, P., Kumar, P., & Singh, A. N. (2019). Oxidative stress and biomarker of TNF-α, MDA and FRAP in hypertension. Journal of Medicine and Life, 2019(3), 253–259. https://doi.org/10.25122/jml-2019-0031.
[18] Armas-Padilla, M. C., Armas-Hernández, M. J., Sosa-Canache, B., Cammarata, R., Pacheco, B., Guerrero, J., Carvajal, A. R., Hernández-Hernández, R., Israili, Z. H., & Valasco, M. (2007). Nitric oxide and malondialdehyde in human hypertension. American Journal of Therapeutics, 14(2), 172–176. https://doi.org/10.1097/01.pap.0000249914.75895.48. [19] Kumar M, Agrawal BK, Mishra A, Meena BS. (2020). A COMPARATIVE STUDY OF MDA LEVEL AS A MARKER OF OXIDATIVE STRESS IN HYPERTENSIVE PATIENTS AND CONTROLS. International Journal of Medical Science and Diagnosis Research (IJMSDR). 4(9):3-5. DOI: https://doi.org/10.32553/ijmsdr.v4i9.669.
[20] Yadav, D. R., Yembarwar, N. K., Guddetwar, S. G., & Geel, V. R. (2022). To Study the Biochemical Changes For Prediction of Essential Hypertension. International Journal of Medical and Biomedical Studies, 6(4), 1–7. https://doi.org/10.32553/ijmbs.v6i4.2496.
[21] Thomas F, Bean K, Guize L, et al. (2002). Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women. Eur Heart J.23:528–35. 10.1053/euhj.2001.2888.
[22] McDonald M, Hertz RP, Unger AN, et al. (2009) Prevalence, awareness, and management of hypertension, dyslipidemia, and diabetes among United States adults aged 65 and older. J Gerontol A Biol Sci Med Sci.64:256–63. 10.1093/gerona/gln016.
[23] Bachir Cherif A, Bennouar S, Bouamra A, et al.( 2018) Prevalence of diabetes and dyslipidemia in hypertensive patients in the area of Blida (Algeria). Annales de Cardiologie et d'Angéiologie 2018;67:198–203. 10.1016/j.ancard. 04.015
[24] Yu S, Yang H, Guo X, et al.. Prevalence of dyslipidemia and associated factors among the hypertensive population from rural northeast China. BMC Public Health 2015;15:1152. 10.1186/s12889-015-2486-7.
[25] Tang, N., Ma, J., Tao, R., Chen, Z., Yang, Y., He, Q., Lv, Y., Lan, Z., & Zhou, J. (2022). The effects of the interaction between BMI and dyslipidemia on hypertension in adults. Scientific Reports, 12(1), 1–7. https://doi.org/10.1038/s41598-022-04968-8.
[26] Zhang Y-Z, Wang L, Zhang J-J, et al.. Vascular peroxide 1 promotes ox-LDL-induced programmed necrosis in endothelial cells through a mechanism involving β-catenin signaling. Atherosclerosis 2018;274:128–38.
[27] ChanCahill, P. A., & Redmond, E. M. (2016). Vascular endothelium - Gatekeeper of vessel health. Atherosclerosis, 248, 97–109.https://doi.org/10.1016/j.atherosclerosis.2016.03.007.
[28] Hurtubise, J., McLellan, K., Durr, K., Onasanya, O., Nwabuko, D., & Ndisang, J. F. (2016). The different facets of dyslipidemia and hypertension in atherosclerosis. Current Atherosclerosis Reports, 18(12). https://doi.org/10.1007/s11883-016-0632-z.
[29] Yue YL, Guo Y, Wang JH. Association of non-enzymatic glycosylation and oxidative stress with angiosclerosis in elderly hypertensive patients. Practical Geriatrics 2014.
[30] Dobrzyńska I, Szachowicz-Petelska B, Weresa J, et al.. Changes in physicochemical properties of kidney cells membrane as a consequence of hypertension and treatment of hypertensive rats with FAAH inhibitor. Chem Biol Interact 2019;299:52–8. 10.1016/j.cbi.2018.11.024. | ||
|
Statistics Article View: 496 PDF Download: 228 |
||